Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases in patients with advanced solid tumors.
Jin Li
No relevant relationships to disclose
Junning Cao
No relevant relationships to disclose
Jian Zhang
No relevant relationships to disclose
Songhua Fan
Employment or Leadership Position - Hutchison MediPharma
Yang Sai
Employment or Leadership Position - Hutchison MediPharma
Hua MU
Employment or Leadership Position - Hutchison MediPharma